Industry Overview

The interventional cardiology and peripheral vascular devices market is expected to reach USD 31.47 Billion by 2021 from USD 21.83 Billion in 2016, at a CAGR of 7.1%.

On the basis of product, the interventional cardiology market is segmented into valve replacement / repair, angioplasty balloons, angioplasty stents, catheters, EVAR stent grafts, IVC filters, plaque modification devices, hemodynamic flow alteration devices, and accessories.

Geographically, the interventional cardiology market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW).

In the Media

General

PCR London Valves

Giovanni Lauricella • 2 min
General, International

EuroPCR 2014 – The Romanticism of Globalization

Giovanni Lauricella • 2 min
General, International

A Headhunter’s Perspective – Reflections on EuroPCR 2014

Holly Scott • 2 min

TMG + Interventional Cardiology

The Mullings Group has enjoyed being on the forefront of structural heart and heart failure by building the technical and commercial teams within the emerging technologies for the valve, occluder, and ventricle device markets on a global scale.

As our firm has run parallel with device development, we have been part of the market transition from TAVR to the mitral valve repair versus replacement to tricuspid valve repair and replacement being the latest buzz words in industry to finally seeing interest in early-stage development of valve durability for lower-risk patients and ground-breaking bioresorbable heart valves.

Our network of KOLs, executives, and R&D experts in the structural heart market combined with our presence at the leading cardiac conferences around the world enable The Mullings Group to be the number one search firm in structural heart.

See Recent Placements

Explore Companies